Zealand Pharma A/S/DKr ZEAL

1D1W1MYTD1Y5YMAX

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company focuses on developing treatments for gastrointestinal and metabolic diseases, including obesity and diabetes. Its product portfolio includes innovative solutions like dasiglucagon, intended for severe hypoglycemia. Founded in 1998, Zealand Pharma leverages proprietary peptide platforms to address unmet medical needs. The company's strategic positioning involves strong partnerships and collaborations with pharmaceutical companies to advance its products through various stages of clinical development.
Ticker
DKr ZEAL
Sector
Health
Primary listing
CSE
Employees
578
Headquarters
Søborg, Denmark
Website
www.zealandpharma.com

ZEAL Metrics

BasicAdvanced
kr 19B
7.09
kr 38.53
0.59
-

Bulls say / Bears say

Survodutide delivered up to 16.6% average weight loss after 76 weeks in the Phase 3 SYNCHRONIZE-1 trial, versus 3.2% for placebo, providing Zealand with a clinically meaningful late-stage asset and potential royalty stream. (Reuters)
Petrelintide’s Phase 2 results supported advancement into a comprehensive Phase 3 program with Roche, while Zealand reported double-digit weight reduction and placebo-like tolerability. Roche’s involvement adds substantial development and commercialization resources to Zealand’s most strategically important obesity program. (Zealand Pharma)
Zealand has substantial financial flexibility: it reported DKK 14.5 billion of cash, cash equivalents, and marketable securities as of March 31, 2026, and launched a share-buyback program of up to USD 200 million. The balance sheet can support continued pipeline investment while reducing near-term financing risk. (Zealand Pharma)
Zealand remains heavily loss-making: Q1 2026 operating expenses were DKK 573 million, while full-year net operating expenses are guided at DKK 2.7–3.3 billion. The investment case therefore still depends on future milestones and successful commercialization rather than recurring product revenue. (Zealand Pharma)
The key obesity assets remain exposed to development and regulatory execution risk: petrelintide was only scheduled to begin Phase 3 in the second half of 2026, while survodutide is being developed and commercialized globally by Boehringer Ingelheim. Delays, disappointing data, or partner reprioritization could materially affect Zealand’s value. (Zealand Pharma)
Even with positive Phase 3 data, survodutide is entering an obesity market led by Eli Lilly and Novo Nordisk; Reuters described Boehringer as trying to catch up with those established leaders. Zealand’s royalty economics may therefore be constrained by intense competition, pricing pressure, and the challenge of commercial differentiation. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.

Funds containing ZEAL

AllUSDEURGBP
Funds
Fund name
Fund size
DKr ZEAL weighting
iShares Healthcare Innovation$HEAL
$1.4B0.29%
iShares Healthcare Innovation€2B78
€1.2B0.29%
iShares Healthcare Innovation£DRDR
£1B0.29%
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.17%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.17%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.